Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI

NACompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 1, 2013

Primary Completion Date

June 1, 2018

Study Completion Date

June 1, 2018

Conditions
Colorectal Cancer
Interventions
DRUG

Regorafenib

Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle

GENETIC

UGT1A1 genotyping (TA6/TA6)

The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2

GENETIC

UGT1A1 genotyping (TA6/TA7)

The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2

GENETIC

UGT1A1 genotyping (TA7/TA7)

The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2

Trial Locations (1)

807

Chung-Ho Memorial Hospital, Kaohsiung Medical University:, Kaohsiung City

All Listed Sponsors
lead

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

NCT03698253 - Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI | Biotech Hunter | Biotech Hunter